A Study Evaluating the Impact of P-tau217 Blood Biomarker Testing on Early Evaluation and Management of Patients Presenting With Cognitive Complaint
← catalyst calendarNCT07140744 · readout ≤ 438 d
Sponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
Not applicable
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Other
Enrollment
7,000estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-08-22 | actual | When the study began enrolling |
| Primary completion | Oct 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Oct 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2025-08-26 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-11-03 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Subjective Cognitive Impairment
Interventions
- Diagnostic test: P-tau217
- Other: Standard of Care
Primary outcome
what the primary-completion date above is the date OFDifference in Proportion of Participants Between the Primary Care Physician (PCP) Tested Group and the PCP Control Group with at Least 1 Management Action
measured 6 Months
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed